- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | bioAffinity Technologies, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 31.07. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | bioAffinity und Pictor kooperieren bei Entwicklung von Tests für Asthma und COPD | 2 | Investing.com Deutsch | ||
| BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 22.07. | bioAffinity partners with Pictor on asthma, COPD tests | 1 | Investing.com | ||
| 22.07. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | bioAffinity reports 200% jump in lung test sales year-over-year | 4 | Investing.com | ||
| 07.07. | bioAffinity: Absatz von Lungenkrebstest steigt im Jahresvergleich um über 200 % | 1 | Investing.com Deutsch | ||
| 30.06. | bioAffinity Technologies, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 22.06. | bioAffinity stellt Forschungsergebnisse zu Hautkrebsbehandlung vor | 2 | Investing.com Deutsch | ||
| 22.06. | bioAffinity to present skin cancer treatment research | 1 | Investing.com | ||
| 18.06. | WallachBeth Capital LLC: WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering | 154 | PR Newswire | JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced... ► Artikel lesen | |
| 18.06. | bioAffinity Technologies closes $3.2M public offering | 1 | Investing.com | ||
| 18.06. | bioAffinity Technologies schließt Kapitalerhöhung über 3,2 Mio. US-Dollar ab | 2 | Investing.com Deutsch | ||
| 16.06. | bioAffinity Technologies, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 16.06. | bioAffinity to participate in veterans lung health webinar | 1 | Investing.com | ||
| 16.06. | bioAffinity Technologies, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 12.06. | bioAffinity Technologies, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 27.05. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | bioAffinity Technologies, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 12.05. | bioAffinity reports 300% jump in lung test sales in April | 1 | Investing.com |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,490 | -2,73 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,207 | +5,08 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,235 | +0,41 % | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
Strategic partnering remains a key priority, with multiple strategic discussions progressing, including... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,172 | +0,79 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| ARROWHEAD PHARMACEUTICALS | 74,84 | -1,29 % | Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events | ||
| ARBUTUS BIOPHARMA | 3,980 | -0,50 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Laufende Fusionskontrollverfahren: Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USA | Datum der Anmeldung:23.07.2026Aktenzeichen:B3-85/26Unternehmen:Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,560 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| ALDEYRA | 1,350 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| ONCO-INNOVATIONS | 0,400 | -0,99 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 5,950 | -0,67 % | AbCellera rises as it will release phase 2 results of menopause asset | ||
| ADAPTIVE BIOTECHNOLOGIES | 21,370 | -0,84 % | Adaptive Biotechnologies Corp - 10-Q, Quarterly Report | ||
| BIOMERIEUX | 73,05 | 0,00 % | BioMerieux H1 Net Sales Slip On Foreign Exchange Impact; Backs Annual Sales Growth Outlook | PARIS (dpa-AFX) - BioMérieux SA (EYWN.MU, BIM.PA), a French biotechnology company, on Tuesday reported an increase in net income for the first half of fiscal 2026, helped by a drop in amortization... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| AC IMMUNE | 2,020 | -0,98 % | AC Immune SA: AC Immune First Half 2026 Financial and Corporate Update | AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances... ► Artikel lesen |
Das Unternehmen BIOAFFINITY TECHNOLOGIES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,510 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.